Kaihua Lu

3.5k total citations
60 papers, 2.5k citations indexed

About

Kaihua Lu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Kaihua Lu has authored 60 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Molecular Biology, 25 papers in Pulmonary and Respiratory Medicine and 25 papers in Oncology. Recurrent topics in Kaihua Lu's work include Lung Cancer Treatments and Mutations (21 papers), Cancer-related molecular mechanisms research (11 papers) and RNA modifications and cancer (11 papers). Kaihua Lu is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Cancer-related molecular mechanisms research (11 papers) and RNA modifications and cancer (11 papers). Kaihua Lu collaborates with scholars based in China, United States and Norway. Kaihua Lu's co-authors include Ming Sun, Meiling Zhang, Weiqin Wu, Zhaoxia Wang, Jing Liu, Xiang-hua Liu, Fengqi Nie, Wei De, Wei Li and Weiping Xie and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Kaihua Lu

57 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kaihua Lu China 24 2.0k 1.5k 412 256 153 60 2.5k
Li Yin China 27 1.4k 0.7× 877 0.6× 505 1.2× 181 0.7× 154 1.0× 99 2.0k
Kai‐Tai Yao China 23 1.3k 0.7× 770 0.5× 745 1.8× 133 0.5× 181 1.2× 74 2.1k
Shouping Xu China 27 1.7k 0.9× 1.5k 1.0× 290 0.7× 562 2.2× 133 0.9× 59 2.3k
Chengwu Zeng China 22 1.6k 0.8× 1.2k 0.8× 323 0.8× 133 0.5× 280 1.8× 60 2.1k
Ming Song China 24 828 0.4× 471 0.3× 459 1.1× 277 1.1× 150 1.0× 92 1.6k
Nadire Duru United States 19 802 0.4× 522 0.3× 407 1.0× 170 0.7× 119 0.8× 26 1.4k
Anne‐Marie Baird Ireland 21 1.0k 0.5× 764 0.5× 316 0.8× 247 1.0× 165 1.1× 61 1.6k
Deborah A. Tweddle United Kingdom 28 1.3k 0.7× 709 0.5× 854 2.1× 120 0.5× 112 0.7× 64 2.2k
Hongling Peng China 24 885 0.4× 470 0.3× 404 1.0× 205 0.8× 217 1.4× 117 1.7k
Huihua Xiong China 20 855 0.4× 458 0.3× 408 1.0× 248 1.0× 89 0.6× 65 1.4k

Countries citing papers authored by Kaihua Lu

Since Specialization
Citations

This map shows the geographic impact of Kaihua Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaihua Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaihua Lu more than expected).

Fields of papers citing papers by Kaihua Lu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaihua Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaihua Lu. The network helps show where Kaihua Lu may publish in the future.

Co-authorship network of co-authors of Kaihua Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Kaihua Lu. A scholar is included among the top collaborators of Kaihua Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaihua Lu. Kaihua Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Qi, et al.. (2024). LRP1B Suppresses Immunotherapy Efficacy in Lung Adenocarcinoma by Preventing Ferroptosis. Cancer Medicine. 13(23). e70486–e70486. 1 indexed citations
2.
Zhang, Shiyu, et al.. (2024). Poor therapeutic outcomes in KRAS-mutant non-small cell lung cancer due to chemoresistance conferred by SLC7A11. Clinical & Translational Oncology. 27(2). 494–506. 2 indexed citations
3.
Wang, Li, et al.. (2024). Efficacy of disitamab vedotin in non-small cell lung cancer with HER2 alterations: a multicenter, retrospective real-world study. Frontiers in Oncology. 14. 1441025–1441025. 2 indexed citations
4.
Jiang, Yingying, et al.. (2023). Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review. Current Oncology. 30(6). 5337–5349. 16 indexed citations
5.
6.
Yu, Changyuan, et al.. (2023). RB1 aberrations predict outcomes of immune checkpoint inhibitor combination therapy in NSCLC. Frontiers in Oncology. 13. 1172728–1172728. 2 indexed citations
7.
Yu, Tao, et al.. (2022). Comprehensive Molecular Analyses of an SLC Family-Based Model in Stomach Adenocarcinoma. Pathology & Oncology Research. 28. 1610610–1610610. 3 indexed citations
8.
Jiang, Yingying, et al.. (2022). Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer. Frontiers in Oncology. 12. 1027664–1027664. 11 indexed citations
9.
Yu, Tao, et al.. (2022). Revolution of CAR Engineering For Next-Generation Immunotherapy In Solid Tumors. Frontiers in Immunology. 13. 936496–936496. 13 indexed citations
10.
Sun, Ming, Peipei Xu, Enxiu Wang, et al.. (2021). Novel two-chain structure utilizing KIRS2/DAP12 domain improves the safety and efficacy of CAR-T cells in adults with r/r B-ALL. Molecular Therapy — Oncolytics. 23. 96–106. 24 indexed citations
11.
Zhao, Jiaojiao, Mei‐Ling Zhang, Qian Wang, et al.. (2019). <p>Ferumoxytol and CpG oligodeoxynucleotide 2395 synergistically enhance antitumor activity of macrophages against NSCLC with EGFR<sup>L858R/T790M</sup> mutation</p>. International Journal of Nanomedicine. Volume 14. 4503–4515. 18 indexed citations
12.
Shi, Xuefei, Bin Wang, Xueren Feng, et al.. (2019). circRNAs and Exosomes: A Mysterious Frontier for Human Cancer. Molecular Therapy — Nucleic Acids. 19. 384–392. 109 indexed citations
13.
Zhang, Meiling, Qian Wang, Yan Ding, et al.. (2018). CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(11). 1792–1797. 24 indexed citations
14.
Liu, Zhili, Zhenyao Chen, Ruihua Fan, et al.. (2017). Over-expressed long noncoding RNA HOXA11-AS promotes cell cycle progression and metastasis in gastric cancer. Molecular Cancer. 16(1). 82–82. 137 indexed citations
15.
Zhang, Meiling, Lingxiang Liu, Jian Wang, et al.. (2015). Effects of High‐Intensity Focused Ultrasound for Treatment of Abdominal Lymph Node Metastasis From Gastric Cancer. Journal of Ultrasound in Medicine. 34(3). 435–440. 5 indexed citations
16.
Chen, Xiaofeng, Quan Zhu, Yiqian Liu, et al.. (2014). Icotinib Is an Active Treatment of Non-Small-Cell Lung Cancer: A Retrospective Study. PLoS ONE. 9(5). e95897–e95897. 25 indexed citations
17.
Cheng, Zhixiang, Yuanying Gong, Yufang Ma, et al.. (2013). Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma. Clinical Cancer Research. 19(7). 1748–1759. 233 indexed citations
18.
Lu, Kaihua, Wei Li, Xiang-hua Liu, et al.. (2013). Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression. BMC Cancer. 13(1). 461–461. 358 indexed citations
19.
Liu, Jing, Kaihua Lu, Zhili Liu, et al.. (2012). MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1. BMC Cancer. 12(1). 519–519. 70 indexed citations
20.
Zhao, Guangfeng, Shuli Zhao, Tingting Wang, et al.. (2011). Estrogen receptor β signaling regulates the progression of Chinese non-small cell lung cancer. The Journal of Steroid Biochemistry and Molecular Biology. 124(1-2). 47–57. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Li Yin Breakdown of academic impact, for papers by Kai‐Tai Yao Breakdown of academic impact, for papers by Shouping Xu Breakdown of academic impact, for papers by Chengwu Zeng Breakdown of academic impact, for papers by Ming Song Breakdown of academic impact, for papers by Nadire Duru Breakdown of academic impact, for papers by Anne‐Marie Baird Breakdown of academic impact, for papers by Deborah A. Tweddle Breakdown of academic impact, for papers by Hongling Peng Breakdown of academic impact, for papers by Huihua Xiong
Rankless by CCL
2026